Man Xu, Ph.D.
- Center for Cancer Research
- National Cancer Institute
Dr. Xu received her Ph.D. at Southwest University, Chongqing, China. She has been a Cell & Molecular Biology Section member since 2017. Dr. Xu is working in the field of studying how MYCN alters the transcriptional landscape of presumptive sympathoadrenal progenitors to cause neuroblastoma. Dr. Xu identified oncoprotein MYCN interacts with members of the core transcriptional regulatory circuitry (CRCs) that maintain NB cell state and identity. Moreover, Dr. Xu found the CRCs protein HAND2 plays an important role in control of NB cell differentiation and growth, and found MYCN is dependent on HAND2 to efficiently bind to DNA and regulate gene transcription to maintain the malignancy of neuroblastoma by using RNA-seq, ChIP-seq and ATAC-seq. This study could provide valuable targets for the development of novel therapeutics in High-risk NB.
Areas of Expertise
1) Transcriptional regulation, 2) Neuroblastoma cell differentiation